ArticleClinical medicine insights. Case reports2025
Severe Neurocognitive Manifestations in Healthy Young Individuals With COVID-19: A Case Series.
Article in Clinical medicine insights. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A growing number of patients suffering from neurocognitive symptoms related to COVID-19 were observed as the pandemic progressed. This article addresses severe neurological manifestations in healthy individuals with COVID-19, which were not previously identified in the absence of comorbidities or respiratory symptoms. Case presentations: The 3 patients, aged between 15 and 27 years old, had no relevant medical history and were not on any chronic treatments. They presented different neurological symptoms (pseudobulbar affect, excessive crying, paracusia, fatigue and sleep problems, anxiety, depression, alexithymia, dementia, aggressive behavior, panic attack, etc) for a period of 2 weeks to 4 months and were treated with different medications. Clomipramine, Zolpidem and Clonazepam were effective in treating these patients. Conclusion: Even in healthy young individuals with COVID-19, severe neurocognitive manifestations could appear with possible long-term consequences. Further research is needed to expand the knowledge on mechanisms, targeted therapeutic strategies and predictors identifying at-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.